CY1110282T1 - Ενωσεις για την αγωγη της απωλειας βαρους - Google Patents

Ενωσεις για την αγωγη της απωλειας βαρους

Info

Publication number
CY1110282T1
CY1110282T1 CY20101100408T CY101100408T CY1110282T1 CY 1110282 T1 CY1110282 T1 CY 1110282T1 CY 20101100408 T CY20101100408 T CY 20101100408T CY 101100408 T CY101100408 T CY 101100408T CY 1110282 T1 CY1110282 T1 CY 1110282T1
Authority
CY
Cyprus
Prior art keywords
patient
receptor antagonist
weight loss
inhibitor
administering
Prior art date
Application number
CY20101100408T
Other languages
English (en)
Inventor
Stefan D Anker
Andrew Coats
Original Assignee
Imperial Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9822458.7A external-priority patent/GB9822458D0/en
Priority claimed from GBGB9822459.5A external-priority patent/GB9822459D0/en
Priority claimed from GBGB9917181.1A external-priority patent/GB9917181D0/en
Application filed by Imperial Innovations Limited filed Critical Imperial Innovations Limited
Publication of CY1110282T1 publication Critical patent/CY1110282T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • External Artificial Organs (AREA)

Abstract

Μέθοδος αγωγής της απώλειας βάρους της οφειλόμενης σε υποκείμενη νόσο σε έναν ασθενή, η οποία μέθοδος περιλαμβάνει τη χορήγηση στον ασθενή μίας αποτελεσματικής ποσότητας ενός παράγοντα ο οποίος μειώνει τη δραστηριότητα του συμπαθητικού νευρικού συστήματος. Μέθοδος αγωγής της απώλειας βάρους της οφειλόμενης σε υποκείμενη νόσο σε έναν ασθενή, η οποία μέθοδος περιλαμβάνει τη χορήγηση στον ασθενή μίας αποτελεσματικής ποσότητας ενός οποιουδήποτε ή περισσότερων από τα ακόλουθα: μίας ενώσεως η οποία αναστέλλει τη δράση της αλδοστερόνης όπως ενός ανταγωνιστή αλδοστερόνης· ενός αναστολέα χυμάσης· ενός αναστολέα καθεψίνης Β· ενός αποκλειστή β-υποδοχέα· ενός ανταγωνιστή υποδοχέα ιμιδαζολίνης· ενός ανταγωνιστή α-υποδοχέα κεντρικής δράσεως· ενός παράγοντα αποκλεισμού γαγγλίων· ενός φαρμάκου το οποίο έχει μία δράση επί των καρδιαγγειακών ανακλαστικών και έτσι μειώνει τη δραστηριότητα του SNS όπως ενός οπιούχου· σκοπολαμίνης ενός ανταγωνιστή ενδοθηλιακού υποδοχέα· και ενός αναστολέα οξειδάσης ξανθίνης. Οι μέθοδοι είναι ιδιαίτερα χρήσιμες στην αγωγή της καρδιακής καχεξίας.
CY20101100408T 1998-10-15 2010-05-10 Ενωσεις για την αγωγη της απωλειας βαρους CY1110282T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9822458.7A GB9822458D0 (en) 1998-10-15 1998-10-15 Methods of treatment
GBGB9822459.5A GB9822459D0 (en) 1998-10-15 1998-10-15 Method of treatment
GBGB9917181.1A GB9917181D0 (en) 1999-07-23 1999-07-23 Methods of treatment
EP99947762A EP1121111B1 (en) 1998-10-15 1999-10-15 Compounds for the treatment of weight loss

Publications (1)

Publication Number Publication Date
CY1110282T1 true CY1110282T1 (el) 2015-01-14

Family

ID=27269516

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100408T CY1110282T1 (el) 1998-10-15 2010-05-10 Ενωσεις για την αγωγη της απωλειας βαρους

Country Status (9)

Country Link
US (2) US7417038B1 (el)
EP (1) EP1121111B1 (el)
JP (1) JP2002527378A (el)
AT (1) ATE457169T1 (el)
CY (1) CY1110282T1 (el)
DE (1) DE69942009D1 (el)
DK (1) DK1121111T3 (el)
PT (1) PT1121111E (el)
WO (1) WO2000021509A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) * 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
EP1689378B1 (en) 2003-12-02 2009-04-15 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1784390A2 (en) 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
IE20050723A1 (en) * 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009149493A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US8946284B2 (en) 2008-08-01 2015-02-03 Arca Biopharma, Inc. Methods and compositions involving (S)-bucindolol
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
GB0907350D0 (en) * 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
SI2523731T1 (sl) 2010-01-14 2019-02-28 Novartis Ag Uporaba sredstva, ki modificira adrenalni hormon
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
KR20130074808A (ko) * 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
ES2698363T3 (es) 2013-03-14 2019-02-04 Actimed Therapeutics Ltd Composiciones de oxprenolol para tratar el cáncer
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
CA3203368A1 (en) 2016-02-26 2017-08-31 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552442A (en) * 1987-09-15 1996-09-03 The Rowett Research Institute Therapeutic applications of clenbuterol
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) * 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
JPH05503510A (ja) * 1989-11-21 1993-06-10 セプラカー・インコーポレーテツド 光学的に純粋な（ｓ）―アテノロールを含む組成物と方法
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
ATE243529T1 (de) * 1995-02-10 2003-07-15 Searle & Co Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
GB9714675D0 (en) 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
ATE457169T1 (de) * 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
CA2398182C (en) * 2000-01-31 2007-03-13 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
DE60229123D1 (de) * 2001-02-20 2008-11-13 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
EP1793818A2 (en) 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
AU2005286733B2 (en) 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1990049A3 (en) 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID)
EP1991270A4 (en) * 2005-12-22 2009-12-02 Anaborex Inc COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
NZ598778A (en) 2006-11-09 2013-09-27 Boehringer Ingelheim Int Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
CA2721739C (en) 2007-04-24 2016-08-23 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
EP3028743A3 (en) 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Compositions for mucositis and oncology therapies

Also Published As

Publication number Publication date
EP1121111B1 (en) 2010-02-10
US20090023639A1 (en) 2009-01-22
WO2000021509A2 (en) 2000-04-20
PT1121111E (pt) 2010-05-17
ATE457169T1 (de) 2010-02-15
DE69942009D1 (de) 2010-03-25
EP1121111A2 (en) 2001-08-08
US7417038B1 (en) 2008-08-26
DK1121111T3 (da) 2010-05-31
JP2002527378A (ja) 2002-08-27
WO2000021509A3 (en) 2000-11-09
US7829596B2 (en) 2010-11-09

Similar Documents

Publication Publication Date Title
CY1110282T1 (el) Ενωσεις για την αγωγη της απωλειας βαρους
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
AU2003268144A8 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
MY114347A (en) Synergistic therapeutic compositions and methods.
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2003045434A3 (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
IS4847A (is) Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2004011018A3 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
WO2005094797A3 (en) Use of ampa-receptor antagonists for treating dementia
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine